CytoMed Therapeutics Limited is a biotechnology company dedicated to the development of innovative therapies that harness the power of the immune system to treat various diseases, including cancer. The company focuses on creating advanced cellular and gene therapies designed to enhance the body’s natural defenses against harmful cells. Through rigorous research and cutting-edge technology, CytoMed aims to bring transformative treatment options to patients, addressing unmet medical needs and improving outcomes in therapeutic areas where traditional methods may fall short. Their commitment to science and patient care positions them as a forward-thinking entity in the biopharmaceutical landscape.
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.25% to 38,618.79 while the NASDAQ rose 0.34% to 15,661.70. The S&P 500 also rose, gaining, 0.34% to 4,971.18.
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a $3.5 million milestone.
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to 13,717.30. The S&P 500, also rose, gaining, 0.26% to 4,420.94.
